CRISPR THERAPEUTICS AG
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $2.40B | $923.0M |
| FY2022 | — | $1.88B | $211.9M |
| FY2023 | — | $1.88B | $389.5M |
| FY2024 | — | $1.93B | $298.3M |
| FY2025 | — | $1.92B | $347.6M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $2.40B | $923.0M |
| FY2022 | — | $1.88B | $211.9M |
| FY2023 | — | $1.88B | $389.5M |
| FY2024 | — | $1.93B | $298.3M |
| FY2025 | — | $1.92B | $347.6M |